Advanced search
Publication Cover
International Journal of General Medicine Volume 16, 2023 - Issue
Submit an article Journal homepage
146
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

A New Risk Score Model Based on Pyrogenic Signatures for the Prediction of Survival and Immune Microenvironment Features in Lung Adenocarcinoma

Lei Zhao1 Thoracic Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, People’s Republic of ChinaView further author information
,
Longfei Wang2 Thoracic Surgery, Ningbo First Hospital, Ningbo, Zhejiang Province, People’s Republic of ChinaView further author information
,
Tao Guo1 Thoracic Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0002-3549-5141View further author information
ORCID Icon,
Chundong Gu1 Thoracic Surgery, the First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, People’s Republic of ChinaCorrespondence[email protected]
View further author information
&
Jinna Wang3 Oncology Department, Dalian Friendship Hospital, Dalian, Liaoning Province, People’s Republic of ChinaCorrespondence[email protected]
View further author information
Pages 2323-2336 | Received 16 Mar 2023, Accepted 17 May 2023, Published online: 08 Jun 2023

References

  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Rocco D, Della Gravara L, Battiloro C, et al. The treatment of advanced lung adenocarcinoma with activating EGFR mutations. Expert Opin Pharmacother. 2021;22(18):2475–2482. doi:10.1080/14656566.2021.1957096
  • Lin JJ, Cardarella S, Lydon CA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556–565. doi:10.1016/j.jtho.2015.12.103
  • Kovacs SB, Miao EA. Gasdermins: effectors of pyroptosis. Trends Cell Biol. 2017;27(9):673–684. doi:10.1016/j.tcb.2017.05.005
  • Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206–214. doi:10.1111/j.1600-065X.2011.01044.x
  • Tang R, Xu J, Zhang B, et al. Ferroptosis, necroptosis, and pyroptosis in anticancer immunity. J Hematol Oncol. 2020;13(1):110. doi:10.1186/s13045-020-00946-7
  • Huang Y, Zhang G, Zhu Q, et al. Role of cytokines released during pyroptosis in non-small cell lung cancer. Cancer Manag Res. 2021;13:7399–7409. doi:10.2147/CMAR.S330232
  • Ruan J, Wang S, Wang J. Mechanism and regulation of pyroptosis-mediated in cancer cell death. Chem Biol Interact. 2020;323(109052). doi:10.1016/j.cbi.2020.109052
  • Xi G, Gao J, Wan B, et al. GSDMD is required for effector CD8(+) T cell responses to lung cancer cells. Int Immunopharmacol. 2019;74(105713). doi:10.1016/j.intimp.2019.105713
  • Zhang Z, Zhang Y, Xia S, et al. Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature. 2020;579(7799):415–420. doi:10.1038/s41586-020-2071-9
  • Chen J, Yang H, Teo ASM, et al. Genomic landscape of lung adenocarcinoma in East Asians. Nat Genet. 2020;52(2):177–186. doi:10.1038/s41588-019-0569-6
  • Ye Y, Dai Q, Qi H. A novel defined pyroptosis-related gene signature for predicting the prognosis of ovarian cancer. Cell Death Discov. 2021;7(1):71. doi:10.1038/s41420-021-00451-x
  • Tibshirani R. Regression shrinkage and selection via the Lasso. J Royal Statistical Soc. 1996;58(1):267–288. doi:10.1111/j.2517-6161.1996.tb02080.x
  • Charoentong P, Finotello F, Angelova M, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–262. doi:10.1016/j.celrep.2016.12.019
  • Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature. 2009;462(7269):108–112. doi:10.1038/nature08460
  • Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–385. doi:10.3322/caac.21565
  • Lin W, Chen Y, Wu B, et al. Identification of the pyroptosis related prognostic gene signature and the associated regulation axis in lung adenocarcinoma. Cell Death Discov. 2021;7(1):161. doi:10.1038/s41420-021-00557-2
  • Zhang G, Yan Z. A new definition of pyroptosis-related gene markers to predict the prognosis of lung adenocarcinoma. Biomed Res Int. 2021;2021(8175003). doi:10.1155/2021/8175003
  • Zhang L, Zhang M, Xu J, et al. The role of the programmed cell death protein-1/programmed death-ligand 1 pathway, regulatory T cells and T helper 17 cells in tumor immunity: a narrative review. Ann Transl Med. 2020;8(22):1526. doi:10.21037/atm-20-6719
  • Thiem A, Hesbacher S, Kneitz H, et al. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression. J Exp Clin Cancer Res. 2019;38(1):397. doi:10.1186/s13046-019-1403-9
  • Buttner R, Gosney JR, Skov BG, et al. Programmed Death-Ligand 1 Immunohistochemistry Testing: a review of analytical assays and clinical implementation in non-small-cell lung cancer. J Clin Oncol. 2017;35(34):3867–3876. doi:10.1200/JCO.2017.74.7642
  • Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421. doi:10.1038/nature12477
  • Huang D, Zhang F, Tao H, et al. Tumor mutation burden as a potential biomarker for PD-1/PD-L1 inhibition in advanced non-small cell lung cancer. Target Oncol. 2020;15(1):93–100. doi:10.1007/s11523-020-00703-3

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.